{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:08:29Z","timestamp":1782385709133,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005562","name":"North Carolina Biotechnology Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005562","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Southeastern Regional Center of Excellence for Emerging Infections and Biodefense","award":["U54 A1057157"],"award-info":[{"award-number":["U54 A1057157"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.vaccine.2011.02.023","type":"journal-article","created":{"date-parts":[[2011,2,24]],"date-time":"2011-02-24T14:17:32Z","timestamp":1298557052000},"page":"3276-3283","source":"Crossref","is-referenced-by-count":42,"title":["Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching"],"prefix":"10.1016","volume":"29","author":[{"given":"Kristina E.","family":"Rehm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Roper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"December (12)","key":"10.1016\/j.vaccine.2011.02.023_bib0005","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.it.2004.10.002","article-title":"25years since the eradication of smallpox: why poxvirus research is still relevant","volume":"25","author":"Mahalingam","year":"2004","journal-title":"Trends Immunol"},{"issue":"January (3)","key":"10.1016\/j.vaccine.2011.02.023_bib0010","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.vaccine.2008.11.019","article-title":"Eczema vaccinatum resulting from the transmission of vaccinia virus from a smallpox vaccinee: An investigation of potential fomites in the home environment","volume":"27","author":"Lederman","year":"2009","journal-title":"Vaccine"},{"issue":"July (1)","key":"10.1016\/j.vaccine.2011.02.023_bib0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacc.2004.05.004","article-title":"Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination","volume":"44","author":"Eckart","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vaccine.2011.02.023_bib0020","article-title":"Expected adverse events in a mass smallpox vaccination campaign","volume":"March","author":"Kemper","year":"2002","journal-title":"Eff Clin Pract"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2011.02.023_bib0025","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3201\/eid1005.030967","article-title":"Smallpox vaccination and adverse cardiac events","volume":"10","author":"Upfal","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"December (21)","key":"10.1016\/j.vaccine.2011.02.023_bib0030","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1001\/jama.294.21.2734","article-title":"Adverse events associated with smallpox vaccination in the United States, January\u2013October 2003","volume":"294","author":"Casey","year":"2005","journal-title":"JAMA"},{"issue":"November","key":"10.1016\/j.vaccine.2011.02.023_bib0035","first-page":"441","article-title":"Investigation of buffalopox outbreaks in Maharashtra State during 1992\u20131996","volume":"106","author":"Kolhapure","year":"1997","journal-title":"Indian J Med Res"},{"issue":"November (2)","key":"10.1016\/j.vaccine.2011.02.023_bib0040","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1006\/viro.2000.0603","article-title":"An emergent poxvirus from humans and cattle in Rio de Janeiro State: Cantagalo virus may derive from Brazilian smallpox vaccine","volume":"277","author":"Damaso","year":"2000","journal-title":"Virology"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2011.02.023_bib0045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jcv.2009.01.007","article-title":"Natural human infections with Vaccinia virus during bovine vaccinia outbreaks","volume":"44","author":"Silva-Fernandes","year":"2009","journal-title":"J Clin Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2011.02.023_bib0050","doi-asserted-by":"crossref","first-page":"e6883","DOI":"10.1371\/journal.pone.0006883","article-title":"Cowpox virus outbreak in banded mongooses (Mungos mungo) and jaguarundis (Herpailurus yagouaroundi) with a time-delayed infection to humans","volume":"4","author":"Kurth","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2011.02.023_bib0055","doi-asserted-by":"crossref","unstructured":"Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, et al. Major increase in human monkeypox incidence 30years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A, 14;107(September (37)):16262-7.","DOI":"10.1073\/pnas.1005769107"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2011.02.023_bib0060","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.4269\/ajtmh.2007.77.1150","article-title":"Prevalence of antibodies against orthopoxviruses among residents of Likouala region, Republic of Congo: evidence for monkeypox virus exposure","volume":"77","author":"Lederman","year":"2007","journal-title":"Am J Trop Med Hyg"},{"issue":"September (1)","key":"10.1016\/j.vaccine.2011.02.023_bib0065","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.virol.2005.05.030","article-title":"Virulence differences between monkeypox virus isolates from West Africa and the Congo basin","volume":"340","author":"Chen","year":"2005","journal-title":"Virology"},{"issue":"May (20)","key":"10.1016\/j.vaccine.2011.02.023_bib0070","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMc062788","article-title":"Monkeypox without exanthem","volume":"356","author":"Lewis","year":"2007","journal-title":"N Engl J Med"},{"issue":"December (Pt 12)","key":"10.1016\/j.vaccine.2011.02.023_bib0075","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1099\/vir.0.83156-0","article-title":"Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara","volume":"88","author":"Meisinger-Henschel","year":"2007","journal-title":"J Gen Virol"},{"issue":"May (Pt 5)","key":"10.1016\/j.vaccine.2011.02.023_bib0080","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J Gen Virol"},{"issue":"March (14)","key":"10.1016\/j.vaccine.2011.02.023_bib0085","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.vaccine.2007.12.059","article-title":"Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine","volume":"26","author":"Ferrier-Rembert","year":"2008","journal-title":"Vaccine"},{"issue":"March (6979)","key":"10.1016\/j.vaccine.2011.02.023_bib0090","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"issue":"June (12)","key":"10.1016\/j.vaccine.2011.02.023_bib0095","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1128\/JVI.79.12.7845-7851.2005","article-title":"Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus","volume":"79","author":"Stittelaar","year":"2005","journal-title":"J Virol"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2011.02.023_bib0100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1128\/IAI.00740-09","article-title":"Prime-boost immunization with adenoviral and modified vaccinia virus ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses","volume":"78","author":"Reyes-Sandoval","year":"2010","journal-title":"Infect Immun"},{"issue":"October (45)","key":"10.1016\/j.vaccine.2011.02.023_bib0105","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1016\/j.vaccine.2009.03.020","article-title":"Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A\/H5N1 viruses","volume":"27","author":"Kreijtz","year":"2009","journal-title":"Vaccine"},{"issue":"September (42)","key":"10.1016\/j.vaccine.2011.02.023_bib0110","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1016\/j.vaccine.2009.07.039","article-title":"Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines","volume":"27","author":"Earl","year":"2009","journal-title":"Vaccine"},{"issue":"June (2)","key":"10.1016\/j.vaccine.2011.02.023_bib0115","first-page":"83","article-title":"Recombinant viruses as tools to induce protective cellular immunity against infectious diseases","volume":"7","author":"Rocha","year":"2004","journal-title":"Int Microbiol"},{"issue":"March (13)","key":"10.1016\/j.vaccine.2011.02.023_bib0120","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1073\/pnas.0401165101","article-title":"Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge","volume":"101","author":"Wyatt","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"27","key":"10.1016\/j.vaccine.2011.02.023_bib0125","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1016\/S0264-410X(01)00075-5","article-title":"Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques","volume":"19","author":"Stittelaar","year":"2001","journal-title":"Vaccine"},{"issue":"November (47)","key":"10.1016\/j.vaccine.2011.02.023_bib0130","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1055\/s-0028-1108143","article-title":"MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)","volume":"99","author":"Stickl","year":"1974","journal-title":"Dtsch Med Wochenschr"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2011.02.023_bib0135","first-page":"253","article-title":"Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA","volume":"107","author":"Mahnel","year":"1994","journal-title":"Berl Munch Tierarztl Wochenschr"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2011.02.023_bib0140","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1089\/aid.2006.0226","article-title":"Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART","volume":"23","author":"Cosma","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2011.02.023_bib0145","first-page":"407","article-title":"IMVAMUNE an attenuated modified vaccinia Ankara virus vaccine for smallpox infection","volume":"10","author":"Jones","year":"2008","journal-title":"Curr Opin Mol Ther"},{"issue":"July\u2013August (4)","key":"10.1016\/j.vaccine.2011.02.023_bib0150","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/rmv.571","article-title":"New generation smallpox vaccines: a review of preclinical and clinical data","volume":"18","author":"Artenstein","year":"2008","journal-title":"Rev Med Virol"},{"issue":"August (16)","key":"10.1016\/j.vaccine.2011.02.023_bib0155","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.1073\/pnas.1233578100","article-title":"Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses","volume":"100","author":"Belyakov","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.vaccine.2011.02.023_bib0160","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1128\/JVI.80.1.306-313.2006","article-title":"Characterization of the vaccinia virus A35R protein and its role in virulence","volume":"80","author":"Roper","year":"2006","journal-title":"J Virol"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2011.02.023_bib0165","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1128\/JVI.01802-09","article-title":"The poxvirus A35 protein is an immunoregulator","volume":"84","author":"Rehm","year":"2010","journal-title":"J Virol"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2011.02.023_bib0170","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.virol.2009.11.008","article-title":"Vaccinia virus A35R inhibits MHC class II antigen presentation","volume":"397","author":"Rehm","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2011.02.023_bib0175","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/JVI.70.6.3753-3762.1996","article-title":"Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene","volume":"70","author":"Roper","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.02.023_bib0180","first-page":"113","article-title":"Rapid preparation of vaccinia virus DNA template for analysis and cloning by PCR","volume":"269","author":"Roper","year":"2004","journal-title":"Methods Mol Biol"},{"issue":"January (Pt 1)","key":"10.1016\/j.vaccine.2011.02.023_bib0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1099\/vir.0.81417-0","article-title":"Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy","volume":"87","author":"Clark","year":"2006","journal-title":"J Gen Virol"},{"issue":"July (13)","key":"10.1016\/j.vaccine.2011.02.023_bib0190","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1128\/JVI.00116-06","article-title":"Obligatory requirement for antibody in recovery from a primary poxvirus infection","volume":"80","author":"Chaudhri","year":"2006","journal-title":"J Virol"},{"issue":"May (10)","key":"10.1016\/j.vaccine.2011.02.023_bib0195","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.4049\/jimmunol.172.10.6265","article-title":"Cellular and humoral immunity against vaccinia virus infection of mice","volume":"172","author":"Xu","year":"2004","journal-title":"J Immunol"},{"issue":"October (1)","key":"10.1016\/j.vaccine.2011.02.023_bib0200","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virol.2005.06.043","article-title":"The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection","volume":"341","author":"Coulibaly","year":"2005","journal-title":"Virology"},{"issue":"August (Pt 8)","key":"10.1016\/j.vaccine.2011.02.023_bib0205","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1099\/vir.0.19120-0","article-title":"IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system","volume":"84","author":"Gherardi","year":"2003","journal-title":"J Gen Virol"},{"issue":"March (Pt 3)","key":"10.1016\/j.vaccine.2011.02.023_bib0210","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1099\/vir.0.81579-0","article-title":"Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus","volume":"87","author":"See","year":"2006","journal-title":"J Gen Virol"},{"issue":"December (11)","key":"10.1016\/j.vaccine.2011.02.023_bib0215","doi-asserted-by":"crossref","first-page":"7550","DOI":"10.4049\/jimmunol.175.11.7550","article-title":"Diversity in the acute CD8 T cell response to vaccinia virus in humans","volume":"175","author":"Jing","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2011.02.023_bib0220","article-title":"Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin","volume":"September","author":"Jones-Trower","year":"2005","journal-title":"Virology"},{"issue":"December (1)","key":"10.1016\/j.vaccine.2011.02.023_bib0225","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.vaccine.2009.09.126","article-title":"Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development","volume":"28","author":"Johnson","year":"2009","journal-title":"Vaccine"},{"issue":"September (1)","key":"10.1016\/j.vaccine.2011.02.023_bib0230","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2567.2007.02607.x","article-title":"Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA","volume":"122","author":"Jin","year":"2007","journal-title":"Immunology"},{"issue":"September (35)","key":"10.1016\/j.vaccine.2011.02.023_bib0235","doi-asserted-by":"crossref","first-page":"14954","DOI":"10.1073\/pnas.0904021106","article-title":"Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response","volume":"106","author":"Oyoshi","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2011.02.023_bib0240","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.jaci.2007.08.004","article-title":"Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation","volume":"120","author":"Scott","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"December (3)","key":"10.1016\/j.vaccine.2011.02.023_bib0245","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1023\/A:1026399916888","article-title":"Vaccinia virus pathogenicity in atopic dermatitis is caused by allergen-induced immune response that prevents the antiviral cellular and humoral immunity","volume":"27","author":"Becker","year":"2003","journal-title":"Virus Genes"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2011.02.023_bib0250","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1128\/JVI.70.10.7103-7107.1996","article-title":"Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo","volume":"70","author":"Sharma","year":"1996","journal-title":"J Virol"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2011.02.023_bib0255","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cellimm.2007.06.005","article-title":"Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II","volume":"246","author":"Yao","year":"2007","journal-title":"Cell Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11002362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11002362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T21:55:43Z","timestamp":1592344543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11002362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":51,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0264410X11002362"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.02.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}